Key result
Novel pharmacological targets for heart failure therapy must focus on direct effects on cardiomyocytes, coronary microcirculation, and myocardial interstitium beyond traditional neurohumoral modulation.
Why the study?
Despite recent therapeutic advances, the prognosis of heart failure patients remains poor, emphasizing the need for novel drug targets beyond neurohumoral and hemodynamic modulation.
This review highlights emerging pharmacological targets for heart failure therapy, specifically focusing on microcirculation, cardiomyocytes, and anti-inflammatory pathways.
Persistent poor HF prognosis despite current therapies leaves open trials of novel cardiomyocyte- and microcirculation-targeted drugs; hypothesis-generating for new pathways.
Despite recent advances in chronic heart failure management (either pharmacological or non-pharmacological), the prognosis of heart failure (HF) patients remains poor. This poor prognosis emphasizes the need for developing novel pathways for testing new HF drugs, beyond neurohumoral and hemodynamic modulation approaches. The development of new drugs for HF therapy must thus necessarily focus on novel approaches such as the direct effect on cardiomyocytes, coronary microcirculation, and myocardial interstitium. This review summarizes principal evidence on new possible pharmacological targets for the treatment of HF patients, mainly focusing on microcirculation, cardiomyocyte, and anti-inflammatory therapy.
No takes yet. Share an insight, caveat, or question.
Correale et al. (2021) conducted a review in Heart Failure. Novel pharmacological targets (microcirculation, interstitium, cardiomyocytes, inflammation) was evaluated. Novel pharmacological targets for heart failure therapy must focus on direct effects on cardiomyocytes, coronary microcirculation, and myocardial interstitium beyond traditional neurohumoral modulation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: